뉴스

"Furnace": Madhya Pradesh Hospital's Burn Ward Patients Suffering In Heat

For burn victims, heat is not merely uncomfortable. It can be dangerous.

Chemotherapy drug supply crisis hits cancer care

Cancer patients in India are facing a critical shortage of life-saving chemotherapy drugs, Cisplatin and Carboplatin, disrupting treatment schedules. Hospitals report dwindling stocks, forcing patients to scramble for supplies. Doctors warn that prolonged unavailability of these essential medicines, with limited alternatives, could negatively impact patient outcomes and survival rates.

Room permit, closed exit: How safety gaps sparked another Delhi tragedy in BnB blaze, killing 21

Most of the victims of the fire, one of Delhi's worst in years, were either people visiting India for their medical treatment or caregivers of patients.

Delhi Hotel Fire: Owner Says Business Boom Prompted Expanding Rooms, Fled Scene After Blaze

Hotel owner Luvkesh Bajaj told police he expanded rooms due to rising demand from patients' attendants. Investigators are verifying his permit claims.

4 dead after massive fire at ICU in Bihar's Muzaffarpur; short circuit suspected

District magistrate Subrata Kumar Sen said that 24 patients were admitted to the hospital, and the ICU in-charge was among those who suffered burns.

10 patients dead, over 20 rescued after massive fire at Bihar hospital

10 patients dead, over 20 rescued after massive fire at Bihar hospital

Malviya Nagar hotel hub serving medical tourists under spotlight after deadly fire

Locals estimate that more than 35 hotels and guest houses operate in the neighbourhood, with many offering budget accommodation for patients and attendants.

Govt plans to standardise organ donation, plug procedural gaps in law

India is overhauling its organ donation framework to include Donation after Circulatory Death, allowing organs to be harvested after the heart stops—not just the brain. This could expand the donor pool for the 70,000-plus patients waiting for kidneys alone.

‘Bharat Bhhagya Viddhaata’ trailer: Kangana Ranaut shines in 26/11 thriller

Kangana Ranaut plays a brave nurse in 'Bharat Bhagya Vidhata', inspired by the true story of hospital staff at Mumbai's Cama and Albless hospitals who saved nearly 400 patients during the 26/11 terror attacks. Directed by Manoj Taparia, the film releases on June 12th alongside three other major releases.

Infections, fractures increasingly driving repeat hip replacement surgeries, finds study

It reflects the large number of young patients with demanding lifestyles who undergo these surgeries and subsequently experience complications.

Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infections. Check details

Shares of Wockhardt soared as much as 19% to their day's high of Rs 2,420 on the BSE on Monday after the company announced that the U.S. Food and Drug Administration (FDA) has approved ZAYNICH (cefepime and zidebactam), a novel intravenous antibiotic for the treatment of adults with complicated urinary tract infections (UTI), including pyelonephritis, caused by susceptible Gram-negative pathogens.According to the company, ZAYNICH combines the fourth-generation cephalosporin cefepime with zidebactam and is designed to target multiple penicillin-binding proteins simultaneously. The antibiotic had earlier received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA.The approval comes at a time when antimicrobial resistance remains a major healthcare challenge. Wockhardt cited data indicating that more than 2.8 million antimicrobial-resistant infections occur annually in the United States, resulting in over 35,000 deaths each year. The company also noted that complicated urinary tract infections account for more than 6,00,000 hospitalisations annually in the U.S., with a growing proportion linked to antimicrobial-resistant and multidrug-resistant bacteria.The FDA's decision was based in part on results from the Phase 3 ENHANCE-1 study, a randomised, double-blind, multicentre trial that evaluated the efficacy, safety and tolerability of ZAYNICH against meropenem in hospitalised adults with complicated urinary tract infections or acute pyelonephritis.In the study, ZAYNICH achieved a composite clinical cure and microbiological response rate of 89% at the test-of-cure visit, compared with 68.4% for meropenem. The treatment difference was 20.6% with a 95% confidence interval of 12.3 to 29.5. The company said the drug was generally well tolerated during the trial.The ENHANCE-1 study enrolled 530 patients across 64 sites spanning the United States, Europe, Latin America, China and India.Wockhardt stated that ZAYNICH targets penicillin-binding proteins PBP 1a/b, 2 and 3 simultaneously, a mechanism that it says provides bactericidal activity against multidrug-resistant Gram-negative bacteria for which treatment options remain limited.The company also disclosed that ZAYNICH received approval from the Drugs Controller General of India (DCGI) on May 27, 2026. In addition, Wockhardt has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency for the antibiotic.Sensex, Nifty today: Catch all the LIVE stock market action here (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

TIMS Sanathnagar inauguration likely on June 11; trial run witnessing 80 patients daily

Five Ebola patients recover in Congo as WHO opens new treatment centre

Five patients infected with a rare Ebola strain have recovered in the Democratic Republic of Congo, with four set for discharge from a new treatment center. This marks the first documented recovery from the Bundibugyo strain, as the WHO urges early medical attention amidst community resistance and a rapidly spreading outbreak.

60% of cancer cases attributed to tobacco consumption

Alarming rise in female patients addicted to chewing

Molecule glue drugs shake up cancer care

One of the biggest advances in pancreatic cancer in decades came out of a crazy idea born in a Harvard University lab.Chemical biologist Gregory Verdine believed you could fight disease-causing proteins hidden inside cells by chemically gluing them to something else in the body and smothering them."Everybody told us this is crazy, that it would never work," he recalls.Revolution Medicines, which bought one of Verdine's companies in 2018, recently announced that one of its drugs doubled the typical survival time for patients with aggressive forms of the disease, from 6.7 months to 13.2 months. The full results from the company's final-stage trial are expected to be the star of the show at the annual confab of cancer doctors in Chicago this weekend.Spurred by the success of RevMed, numerous companies are now racing to develop similar drugs, dubbed "molecular glues", which can be used to treat a variety of ailments. And investors and pharmaceutical companies with deep pockets are chasing after them, creating one of the hottest corners of dealmaking in the industry.Also read | India's out-of-pocket healthcare spending drops significantly, govt data showsIt's not unusual for exciting new drugs to spark surges in stock prices and dealmaking frenzy. But molecular glue is a particularly complicated science, and the startups pursuing technologies similar to RevMed are mostly in early stages of testing. Their medicines won't be ready for years, if ever.That hasn't stopped big drugmakers such as Novartis, Roche Holding and Eli Lilly from inking research pacts with glue developers that could pay out billions of dollars in milestones.The boom has been especially lucrative for Monte Rosa Therapeutics. Over the past three years, the Boston-based biotech firm has signed three agreements that could be worth over $10 billion to develop molecular glue drugs with both Novartis and Roche.The company, which trades under the stock ticker GLUE, has seen its shares surge nearly 400% over the past year. It's preparing to start mid-stage trials for multiple drugs by the end of this year."The run-up in the share price is justified based on what we've seen so far," says Robert Driscoll, an analyst at Wedbush. Gains are "due to the success of their drugs rather than kind of exuberance around the glue technology as a whole", he says.Science of GlueMolecular glues work in a fundamentally different way from other oral medicines. Most pills - like Prozac for depression or Lipitor for cholesterol - are tiny chemicals that squeeze into a pocket inside a much larger protein to gum up its functioning. But many proteins have few obvious pockets, including key cancer-causing proteins.In fact, about 80% of all proteins in the body are what scientists refer to as "undruggable", meaning they can't be targeted with traditional drug technologies.RevMed's daraxonrasib cleverly circumvents this problem by acting as a molecular stickum. Once inside the body it binds to a healthy protein on one side and then draws in the bad protein to stick to the other side. The healthy protein helps block the bad protein and turn off its signalling.Competitors Line UpMultiple companies are chasing RevMed's lead in pancreatic cancer despite the long odds. San Diego-based Erasca is in early stages of testing a drug it says is more potent than daraxonrasib. Japanese drugmaker Astellas Pharma has begun final-stage trials of a degrader that may help a subset of pancreatic and lung cancer patients.Molecular glues are also being developed as alternatives to injectable drugs used to treat autoimmune and skin disorders. Shares of Kymera Therapeutics have soared more than 180% in the past year thanks to promising early trial results. The company is developing a once-daily pill it hopes will one day compete with Sanofi and Regeneron Pharmaceuticals' Dupixent, one of the world's bestselling drugs."The technology allows you to go after things that would have been almost impossible" to do previously with pills, says Nello Mainolfi, Kymera's founder and CEO.With few effective options for pancreatic cancer, analysts expect RevMed's daraxonrasib to become an enormous bestseller for the company.Prospects for daraxonrasib and speculation about a potential takeout deal have inflated RevMed's market cap to nearly $33 billion. That's a lofty figure for a drugmaker with no approved medicines.The company is preparing to file for US approval soon, and the FDA has promised to give the drug an ultrafast review. It's projected to reach $7 billion in sales a year by 2032, according to the average of estimates compiled by Bloomberg.

WHO announces 1st Ebola recovery in Congo

The World Health Organization on Friday announced the first recovery of a confirmed Ebola patient in the outbreak raging in the Democratic Republic of Congo."The DRC has said that on May 27, a patient recovered and left the hospital and has been discharged into the community," the WHO's Anais Legand told reporters.She said it marked the "first" among patients who had been confirmed to have Ebola, but stressed that she expected there had been other recoveries among people who have not yet received laboratory confirmation of test results."This is the first one" to be discharged from a care centre "following two negative tests", said Legand, a WHO technical officer on viral haemorrhagic fevers.She said the WHO had to date recorded 17 confirmed and 223 suspected Ebola deaths in the DR Congo since the outbreak was declared on May 15, out of 125 confirmed cases and over 900 suspected cases.In neighbouring Uganda, seven cases have also been confirmed, including one death.

Why 8 in 10 patients turn to internet after doctor visits

A recent survey reveals a significant "patient confusion crisis" in Delhi-NCR, with nearly 80% of patients seeking online clarification post-doctor visits. Many feel rushed, lack guidance on next steps, and struggle to navigate hospitals, leading to increased costs and stress. Experts highlight overcrowded OPDs and weak guidance systems as key issues.

Wockhardt shares jump 8%, extend rally after CDSCO nod for Zaynich antibiotic

Wockhardt shares rallied sharply on Friday, surging 7.87% to hit Rs 1,910.50 after the pharmaceutical company received a major regulatory boost for its breakthrough antibiotic, Zaynich. Notably, the stock has climbed nearly 12% in just the last two trading sessions, reflecting strong investor optimism following the development.In an exchange filing, Wockhardt announced that the Central Drugs Standard Control Organisation (CDSCO) has approved the import and marketing of its indigenously discovered and developed first-in-class antibiotic, Zaynich (Zidebactam/Cefepime), in India.The approval covers the treatment of adult patients suffering from complicated urinary tract infections (cUTI), including pyelonephritis, as well as cases involving concurrent Gram-negative bacteremia.The nod is backed by strong results from the pivotal ENHANCE-1 Phase 3 clinical trial, a multinational, randomised, double-blind study comparing Zaynich with Meropenem — one of the widely used antibiotics for severe infections.The results significantly favoured Zaynich. The study showed that 89% of patients treated with Zaynich achieved clinical cure and microbiological eradication, compared with 68.4% in the Meropenem arm, delivering a treatment advantage of 20.6%.Even more striking were the outcomes in high-risk bacteremia patients, where Zaynich posted an 89% response rate versus just 44% for Meropenem, highlighting its potential as a game-changing therapy in severe drug-resistant infections.The company stated that Zaynich could emerge as a critical weapon against carbapenem-resistant infections — an area where existing treatment options like colistin and polymyxins often face limitations due to toxicity and weaker efficacy. Importantly, the drug is designed to combat metallo-β-lactamase (MBL)-mediated resistance, one of the toughest and most widespread antibiotic resistance mechanisms in India.Wockhardt Shares: Price trend and technical outlookWockhardt shares have surged nearly 27% over the past month, while the stock has skyrocketed an astounding 946% in the last three years, turning investor wealth nearly 10-fold during the period. The company currently commands a market capitalisation of around Rs 28,777 crore.On the technical front, Trendlyne data indicates that Wockhardt’s 14-day Relative Strength Index (RSI) stands at 72.3. An RSI above 70 is generally considered overbought, suggesting the stock could witness some profit-booking or a short-term pullback after the recent sharp rally.However, the overall trend remains firmly bullish, with the stock trading above all 8 out of 8 key simple moving averages (SMAs), indicating sustained strength in momentum.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

India’s Health Spend Up 2.7 Times In A Decade, But Here’s Why Patients Still Feel The Pinch

New government data shows public health spending has risen sharply over ten years. Experts say the numbers tell only part of the story

Babulal Marandi seeks CBI probe into alleged scam in Jharkhand’s Health Department

Leader of the Opposition in the Jharkhand Assembly said that the life-saving medicines worth crores of rupees have expired while lying in the warehouses, and the medicines purchased never reached the patients.